You have full access to this article via your institution. Figure 1: A family with multiple GISTs and mutation of the KIT gene.

GIST, which is often driven by KIT or PDGFRA mutations, is effectively managed with Gleevec, a tyrosine kinase inhibitor approved for advanced, metastatic and relapsed/refractory disease. While ...

Advanced SDH-deficient GISTs are usually treated with the same therapies targeting KIT and PDGFRA receptors as those used in metastatic GIST. However, these treatments display less activity in the ...

The tyrosine kinase inhibitor imatinib targets the human KIT receptor and the platelet-derived growth factor receptor-α. This drug exhibits impressive antitumor effects against GIST and has ...

The first part – which was approved in January – covered the use of the drug in GIST patients with a platelet-driven growth factor receptor alpha (PDGFRa) exon 18 mutation, including PDGFRA ...

IDRX-42 has demonstrated activity against all key primary and secondary KIT mutations, designed to improve outcomes for patients with GIST. Updated clinical data from StrateGIST 1, an ongoing ...

designed to address both primary and secondary KIT mutations in patients with GIST. Early data from the StrateGIST 1 Phase I/Ib trial demonstrated promising antitumor activity, with an objective ...

Bezuclastinib is COGT’s main value driver, currently undergoing 3 late-stage trials for SM and GIST. COGT’s SUMMIT ... This is a KIT mutation inhibitor that has the potential to be a best ...

[25] In view of these data, imatinib has become the first-line treatment for patients presenting with advanced GIST. Since the 800 mg dose causes more pronounced toxic effects but equivalent ...